| Name | parathyroid hormone |
|---|---|
| Synonyms | PTH; Parathormone; Parathyrin; Parathyroid hormone; Parathyroid hormone precursor; Parathormones; Parathyrins; Parathyroid hormones… |
| Name | ergocalciferol |
|---|---|
| CAS |
| PubMed | Abstract | RScore(About this table) | |
|---|---|---|---|
| 16022093 | Shah N, Bernardini J, Piraino B: Prevalence and correction of 25 (OH) deficiency in peritoneal dialysis patients. Perit Dial Int. 2005 Jul-Aug;25(4):362-6. Patients deficientin 25 (OH) were given ergocalciferol, 50000 IU orally once per week for 4 weeks. Serum calcium, parathyroid hormone (PTH), and 25 (OH) and 1,25 (OH) 2 levels were obtained before and after treatment. |
1(0,0,0,1) | Details |
| 20091666 | Geary DF, Hodson EM, Craig JC: Interventions for bone disease in children with chronic kidney disease. . Cochrane Database Syst Rev. 2010 Jan 20;(1):CD008327. No significant differences were detected in growth rates, bone histology or biochemical parameters between and either dihydrotachysterol or ergocalciferol (2 RCTs). |
0(0,0,0,0) | Details |
| 17591525 | Al-Aly Z, Qazi RA, Gonzalez EA, Zeringue A, Martin KJ: Changes in serum and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD. Am J Kidney Dis. 2007 Jul;50(1):59-68. The effect of ergocalciferol administration on serum and plasma intact parathyroid hormone (PTH) levels in these patients is not known. |
0(0,0,0,0) | Details |
| 10100926 | Gagnemo-Persson R, Persson P, Bryngelsson T, Green B, Hakanson R: Rat stomach ECL-cell histidine decarboxylase activity is suppressed by ergocalciferol but unaffected by parathyroid hormone and calcitonin. Regul Pept. 1999 Feb 5;79(2-3):131-9. |
32(0,1,1,2) | Details |
| 17199797 | DeVille J, Thorp ML, Tobin L, Gray E, Johnson ES, Smith DH: Effect of ergocalciferol supplementation on serum parathyroid hormone and serum in chronic kidney disease. Nephrology. 2006 Dec;11(6):555-9. |
13(0,0,2,3) | Details |
| 9262512 | Gagnemo-Persson R, Samuelsson A, Hakanson R, Persson P: Chicken parathyroid hormone gene expression in response to gastrin, ergocalciferol, and restricted food intake. Calcif Tissue Int. 1997 Sep;61(3):210-5. |
12(0,0,2,2) | Details |
| 16644777 | Boudville NC, Hodsman AB: Renal function and concentrations predict parathyroid hormone levels in renal transplant patients. Nephrol Dial Transplant. 2006 Sep;21(9):2621-4. Epub 2006 Apr 27. BACKGROUND: Recent guidelines suggest supplementation with ergocalciferol (2)) in chronic kidney disease stages 3 and 4 patients with elevated parathyroid hormone (PTH) levels and (25OHD) levels <75 nmol/l. |
7(0,0,1,2) | Details |
| 19342361 | Pepper KJ, Judd SE, Nanes MS, Tangpricha V: Evaluation of repletion regimens to correct status in adults. Endocr Pract. 2009 Mar;15(2):95-103. Serum levels of parathyroid hormone, (25-OHD), and were compared before and after treatment with ergocalciferol. |
6(0,0,1,1) | Details |
| 19229237 | Ramjan KA, Roscioli T, Rutsch F, Sillence D, Munns CF: Generalized arterial calcification of infancy: treatment with bisphosphonates. Nat Clin Pract Endocrinol Metab. 2009 Mar;5(3):167-72. At 12 months, ergocalciferol was added at a dose of 5,000 U daily for 6 weeks, followed by 200 U daily owing to the patient's deficiency and elevated parathyroid hormone level. |
6(0,0,1,1) | Details |
| 18242158 | Pitukcheewanont P, Numbenjapon N, Costin G: Ectopic thymic parathyroid adenoma and vitamin D deficiency rickets: a 5-year-follow-up case report and review of literature. Bone. 2008 Apr;42(4):819-24. Epub 2007 Oct 22. Following the intramuscular administration of 125,000 U ergocalciferol he developed hypercalcemia with persistently elevated parathyroid hormone (PTH) levels suggestive of primary hyperparathyroidism. |
6(0,0,1,1) | Details |
| 17215573 | Zisman AL, Hristova M, Ho LT, Sprague SM: Impact of ergocalciferol treatment of deficiency on serum parathyroid hormone concentrations in chronic kidney disease. Am J Nephrol. 2007;27(1):36-43. Epub 2007 Jan 11. |
6(0,0,1,1) | Details |
| 2488496 | Lepoutre JL, Thevenon A, Defrance-David T, Fournier P, Racadot A, Dewailly P: [comparison of the effects on phosphocalcic metabolism and bone of 3 protocols of administration in the elderly]. Rev Med Interne. 1989 Sep-Oct;10(5):475-81. The administration of either oral in doses of 4,000 IU per day, or six-monthly intramuscular injections of ergocalciferol 600,000 IU, combined with a daily intake of at least 1 g of brings back to normal both 25 OH D concentrations and parathyroid hormone levels. |
6(0,0,1,1) | Details |
| 6294581 | Aarskog D, Aksnes L, Markestad T: Effect of parathyroid hormone on cAMP and formation and renal handling of in vitamin D-dependent rickets. Pediatrics. 1983 Jan;71(1):59-63. The concentration of 1,25 [OH] 2D was markedly decreased even when she was receiving a daily dose of 25,000 IU of ergocalciferol. |
3(0,0,0,3) | Details |
| 7569451 | Gonzalez F, Gomez C, Ayala A, Roessler E: [Hypophosphatemic osteomalacia acquired after renal transplantation: a a cause of severe osteoporosis]. Rev Med Chil. 1995 Jan;123(1):85-9. The patient had good renal function, a parathormone independent hyperphosphaturia, normal 25-OH increased urinary decreased osteocalcin, reduced bone density and a bone biopsy revealing osteomalacia. The diagnosis of hypophosphatemic osteomalacia was reached and treatment with phosphates and ergocalciferol was started but, despite this, the patient suffered a new fracture two years later. |
2(0,0,0,2) | Details |
| 2114209 | Weinstein RS, Harris RL: Hypercalcemic hyperparathyroidism and hypophosphatemic osteomalacia complicating neurofibromatosis. Calcif Tissue Int. 1990 Jun;46(6):361-6. When hypercalcemia and elevated levels of parathyroid hormone are found in osteomalacia, however, it may be difficult to determine if the hyperparathyroidism was primary or tertiary. Serial biomechanical, bone biopsy, and densitometric studies confirmed that treatment with ergocalciferol, and supplements significantly improved the osteomalacia but caused increased parathyroid overactivity. |
2(0,0,0,2) | Details |
| 18308659 | Camacho PM, Painter S, Kadanoff R: Treatment of adult hypophosphatasia with teriparatide. Endocr Pract. 2008 Mar;14(2):204-8. METHODS: A 75-year-old woman with hypophosphatasia was treated with ergocalciferol and supplements for 2 years. At baseline, she had mild secondary hyperparathyroidism (intact parathyroid hormone, 76 pg/mL; reference range, 10 to 65), which was corrected by the supplementation and therapy. |
2(0,0,0,2) | Details |
| 18463042 | Alzahrani AS, Al Sheef M: Severe primary hyperparathyroidism masked by asymptomatic celiac disease. . Endocr Pract. 2008 Apr;14(3):347-50. Laboratory data (and reference ranges) were as follows: serum calcium, 2.34 mmol/L (2.1 to 2.6); 0.91 mmol/L (0.90 to 1.50); alkaline phosphatase, 421 U/L (40 to 135); albumin, 37 g/L (35 to 45); parathyroid hormone, 874 ng/L (15 to 65); urine 3.76 mmol/d (2.5 to 8); and <13 nmol/L (22 to 116). She was treated with increasing doses of ergocalciferol, and but the serum concentration did not increase substantially (reaching a maximum of 2.70 mmol/L on suprapharmacologic doses of these agents). |
1(0,0,0,1) | Details |
| 15664003 | Sato Y, Kanoko T, Satoh K, Iwamoto J: and with supplements prevent nonvertebral fracture in elderly women with Alzheimer's disease. Bone. 2005 Jan;36(1):61-8. Epub 2004 Nov 24. In a random and prospective study of AD patients, 100 patients received 45 mg 1000 IU ergocalciferol and 600 mg daily for 2 years, and the remaining 100 (untreated group) did not. They also had high serum levels of parathyroid hormone (PTH) and osteocalcin (OC) and low serum ionized indicating that deficiency stimulates compensatory PTH secretion. |
1(0,0,0,1) | Details |
| 17389892 | Hernandez JD, Wesseling K, Boechat MI, Gales B, Salusky IB: Osteomalacia in a hemodialysis patient receiving an active sterol. Nat Clin Pract Nephrol. 2007 Apr;3(4):227-32. INVESTIGATIONS: The patient underwent a physical examination, and his serum levels of alkaline phosphatase, parathyroid hormone, aluminum and (25OH- were determined. MANAGEMENT: Monthly therapy with ergocalciferol and discontinuation of paricalcitol. |
1(0,0,0,1) | Details |
| 9062528 | Zeghoud F, Vervel C, Guillozo H, Walrant-Debray O, Boutignon H, Garabedian M: Subclinical deficiency in neonates: definition and response to supplements. Am J Clin Nutr. 1997 Mar;65(3):771-8. To determine the biological criteria for neonatal deficiency, serum parathyroid hormone (PTH), phosphates, and alkaline phosphatase (ALP) activity were measured during the winter-spring period in 80 healthy neonates and their mothers 3-6 d after delivery. A longitudinal 3-mo survey of the serum biology of 52 of these neonates consuming formula was also performed to test the influence of their neonatal status on the effects of two oral ergocalciferol supplements (500 and 1000 IU or 12.5 and 25 micrograms/d). |
1(0,0,0,1) | Details |
| 3889260 | Hillman LS, Hollis B, Salmons S, Martin L, Slatopolsky E, McAlister W, Haddad J: Absorption, dosage, and effect on mineral homeostasis of in premature infants: comparison with 400 and 800 IU supplementation. J Pediatr. 1985 Jun;106(6):981-9. Administration of 800 IU ergocalciferol (D2) also produced significantly higher serum 25-OHD concentrations than those in infants given 400 IU but increases in serum 25-OHD were more gradual than in infants given 25-OHD3. Infants given 2 micrograms/kg BW 25-OHD3 had a significant increase in serum values, but a decrease in serum and concentrations, and parathyroid hormone also was suppressed to low normal values. |
1(0,0,0,1) | Details |
| 19553166 | Maheut H, Chevriot F, Marty H, Lavaud S, Kazes I, Chanard J, Rieu P: [Why and how correct deficiency in haemodialysis patients?] . Nephrol Ther. 2009 Nov;5(6):542-9. Epub 2009 Jun 23. The efficacy of an oral supplementation for 6 months with ergocalciferol, was evaluated in a monocentric cohort of 107 prevalent hemodialysis patients. Plasma levels of 25 (OH) D, parathormone, total and ionized phosphates, were measured at month 0, 3 and 6 in all patients and plasma levels of 1-25 (OH) D at month 0 and 6 in 38 patients with the lowest 25 (OH) D levels at baseline. |
1(0,0,0,1) | Details |
| 8865145 | Heikinheimo R, Sievanen H, Jantti P, Maki-Jokela PL, Rajala S, Vuori I: treatment and bone mineral density in the aged. Maturitas. 1996 May;23 Suppl:S77-80. The bone mineral density in the distal forearm and femoral neck did not differ between nine residents (mean age 81.0 years) of an old peoples' home who had received an annual injection of 150,000 IU ergocalciferol during the foregoing 2-7 years (mean 5.1 years) and nine age-, weight- and height-matched control subjects who had subnormal level. The alkaline phosphatase and parathyroid hormone levels were clearly higher when the level was below 10 nmol/1. |
1(0,0,0,1) | Details |
| 18575896 | Menon S, Valentini RP, Hidalgo G, Peschansky L, Mattoo TK: insufficiency and hyperparathyroidism in children with chronic kidney disease. Pediatr Nephrol. 2008 Oct;23(10):1831-6. Epub 2008 Jun 25. Blood levels of 25 (OH) D3, and parathormone (PTH) were examined in 57 children (40 boys; mean age 10.6 years). Following ergocalciferol treatment (22), PTH decreased from 122.13 +/- 82.94 ng/ml to 80.14 +/- 59.24 ng/ml (p < 0.001) over a period of 3 months. |
1(0,0,0,1) | Details |
| 12361778 | Heer M: Nutritional interventions related to bone turnover in European space missions and simulation models. Nutrition. 2002 Oct;18(10):853-6. However, parathyroid hormone and levels decreased significantly. As a consequence of these results, we examined in the 21-d Mir 97 mission a preventative dietary approach of high intake of at least 1000 mg/d with supplementation (650 IU/d of Ergocalciferol) and constant intake (180 mEq/d). |
1(0,0,0,1) | Details |
| 15059059 | Prince RL, Glendenning P: 8: Disorders of bone and mineral other than osteoporosis. . Med J Aust. 2004 Apr 5;180(7):354-9. Cancers can produce bone lysis through direct spread within the skeleton or production of endocrine parathyroid hormone-like factors; treatment is with a bisphosphonate, plus appropriate therapy for the cancer. Hypocalcaemia may result from severe decrease in absorbed or lack of parathyroid action; both are treated with and (ergocalciferol or |
1(0,0,0,1) | Details |
| 941867 | Medalle R, Waterhouse C, Hahn TJ: resistance in magnesium deficiency. . Am J Clin Nutr. 1976 Aug;29(8):854-8. Pharmacological doses of either ergocalciferol or dihydrotachysterol did not correct the hypocalcemia except in one patient who had a minimal rise in serum While the mechanism remains speculative, it appears that facilitates the release of from bone in the presence of adequate amounts of and parathormone. |
1(0,0,0,1) | Details |
| 19631774 | Glendenning P, Chew GT, Seymour HM, Gillett MJ, Goldswain PR, Inderjeeth CA, Vasikaran SD, Taranto M, Musk AA, Fraser WD: Serum levels in -insufficient hip fracture patients after supplementation with ergocalciferol and Bone. 2009 Nov;45(5):870-5. Epub 2009 Jul 23. Secondary endpoints included 25OHD measured by radioimmunoassay (RIA), intact parathyroid hormone (iPTH), and bioactive (1-84) whole PTH (wPTH). |
1(0,0,0,1) | Details |
| 10966885 | Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF: Decreased bioavailability of in obesity. Am J Clin Nutr. 2000 Sep;72(3):690-3. OBJECTIVE: This study assessed whether obesity alters the cutaneous production of (3) or the intestinal absorption of (2) (ergocalciferol). RESULTS: Obese subjects had significantly lower basal concentrations and higher parathyroid hormone concentrations than did age-matched control subjects. |
1(0,0,0,1) | Details |
| 11335767 | Carvalho NF, Kenney RD, Carrington PH, Hall DE: Severe nutritional deficiencies in toddlers resulting from health food milk alternatives. Pediatrics. 2001 Apr;107(4):E46. The 25-- level was low (7.7 pg/mL) and the parathyroid hormone level was markedly elevated (114 pg/mL). The patient was treated with ergocalciferol and supplements. |
1(0,0,0,1) | Details |
| 6967875 | Lund B, Sorensen OH, Lund B, Bishop JE, Norman AW: metabolism in hypoparathyroidism. . J Clin Endocrinol Metab. 1980 Sep;51(3):606-10. Only moderately reduced serum [1,25 (OH) 2D3] levels were found in 13 hypoparathyroid patients and in 1 pseudohypoparathyroid patient, indicating that factors other than parathyroid hormone are able to mediate the basal production of 1,25 (OH) 2D3. The serum 25OHD and 1,25 (OH) 2D concentrations were followed during the change of treatment from ergocalciferol to 1 alpha-hydroxycholecalciferol (1 alpha-OHD3). |
1(0,0,0,1) | Details |
| 18492750 | Romagnoli E, Mascia ML, Cipriani C, Fassino V, Mazzei F, D'Erasmo E, Carnevale V, Scillitani A, Minisola S: Short and long-term variations in serum calciotropic hormones after a single very large dose of ergocalciferol or in the elderly. J Clin Endocrinol Metab. 2008 Aug;93(8):3015-20. Epub 2008 May 20. OBJECTIVE: Our objective was to evaluate the effects of a single very large dose of both calciferols on serum changes of [25 (OH) D], [1,25 (OH)(2) D], ionized calcium, and parathyroid hormone (PTH) at baseline, and at 3, 7, 30, and 60 d. |
1(0,0,0,1) | Details |
| 15690240 | Zaidi AN, Ceneviva GD, Phipps LM, Dettorre MD, Mart CR, Thomas NJ: Myocardial calcification caused by secondary hyperparathyroidism due to dietary deficiency of and Pediatr Cardiol. 2005 Jul-Aug;26(4):460-3. Treatment consisted of adequate daily replacement of and ergocalciferol. On follow-up, her parathyroid hormone level was significantly reduced and substantially reduced cardiac calcifications were seen on echocardiogram. |
1(0,0,0,1) | Details |
| 16490909 | Crawford BA, Kam C, Pavlovic J, Byth K, Handelsman DJ, Angus PW, McCaughan GW: Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2006 Feb 21;144(4):239-48. Differences between groups in percentage change from baseline adjusted for baseline weight and serum parathyroid hormone (PTH) level were 4.0% (95% CI, 1.1% to 7.0%) for the lumbar spine, 4.7% (CI, 1.9% to 7.6%) for the femoral neck, and 3.8% (CI, 1.7% to 6.0%) for the total hip. All patients received supplementation with 600 mg/d, and ergocalciferol, 1000 U/d. |
1(0,0,0,1) | Details |
| 18238737 | Andress DL, Coyne DW, Kalantar-Zadeh K, Molitch ME, Zangeneh F, Sprague SM: Management of secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease. Endocr Pract. 2008 Jan-Feb;14(1):18-27. Appropriate treatment involves suppression of parathyroid hormone (PTH) to normal levels with active therapy and binders. Ergocalciferol or should be used to correct levels either before or during active therapy. |
1(0,0,0,1) | Details |
| 16286516 | Manco M, Calvani M, Nanni G, Greco AV, Iaconelli A, Gasbarrini G, Castagneto M, Mingrone G: Low does not affect insulin sensitivity in obesity after bariatric surgery. Obes Res. 2005 Oct;13(10):1692-700. RESULTS: Prevalence of hypovitaminosis D was 76% in the obese status and 91% and 89% at 5 and 10 years after BPD, respectively, despite ergocalciferol supplementation. 25 (OH) D concentration decreased from 39.2 +/- 22.3 in obesity (p = 0.0001) to 27.4 +/- 16.4 and 25.1 +/- 13.9 nM 5 and 10 years after BPD, respectively. Parathormone correlated with fat mass (R2 = 0.19; p = 0.0001) and BMI (R2 = 0.053; p = 0.01) and inversely with M value (R2 = 0.16; p = 0.0001), but only in obese subjects. |
1(0,0,0,1) | Details |
| 3877585 | Hodson EM, Evans RA, Dunstan CR, Hills E, Wong SY, Rosenberg AR, Roy LP: Treatment of childhood renal osteodystrophy with or ergocalciferol. Clin Nephrol. 1985 Oct;24(4):192-200. Plasma levels rose while parathyroid hormone and alkaline phosphatase levels fell following both treatments, and were unchanged in non-compliant children. |
1(0,0,0,1) | Details |
| 18558303 | Blair D, Byham-Gray L, Lewis E, McCaffrey S: Prevalence of [25 (OH) D] deficiency and effects of supplementation with ergocalciferol in stage 5 chronic kidney disease patients. J Ren Nutr. 2008 Jul;18(4):375-82. Measures of interest included serum albumin, glycosylated hemoglobin (HgA1c), hemoglobin, corrected parathyroid hormone (iPTH), equilibrated normalized protein catabolic rate (enPCR), and quality-of life-survey physical component score (SF-36 PCS). |
1(0,0,0,1) | Details |
| 16898852 | Ziolkowska H: Minimizing bone abnormalities in children with renal failure. . Paediatr Drugs. 2006;8(4):205-22. Parathyroid hormone (PTH) levels in children with CRF should be within the normal range, but in children with end-stage renal disease PTH levels should be two to three times the upper limit of the normal range. In children with CRF, ergocalciferol (2)), (3)), and (3)) should be used as analogs. |
1(0,0,0,1) | Details |
| 18421544 | Przybelski R, Agrawal S, Krueger D, Engelke JA, Walbrun F, Binkley N: Rapid correction of low status in nursing home residents. Osteoporos Int. 2008 Nov;19(11):1621-8. Epub 2008 Apr 18. SUMMARY: This prospective study finds that ergocalciferol 50,000 IU three times weekly for four weeks effectively and safely corrects inadequacy in nursing home residents. Serum total 25 (OH) D, 25 (OH) D (2), 25 (OH) D (3), parathyroid hormone (PTH), bone turnover markers and neuro-cognitive assessments were obtained at baseline and four weeks. |
1(0,0,0,1) | Details |
| 7994333 | Brisse F, Breton D, Gagey V, Cheron G: [Convulsions and neonatal hypoparathyroidism revealing maternal hyperparathyroidism]. Arch Pediatr. 1994 Mar;1(3):255-9. BACKGROUND: Severe prolonged hypocalcemia may occur in neonates whose parathyroid hormone production has been blocked by maternal hyperparathyroidism. The baby had been given milk-formula plus ergocalciferol, 1,200 IU/day. |
1(0,0,0,1) | Details |
| 8292858 | Nomura K, Noguchi Y, Yoshikawa T, Fukuzawa K, Makino T, Tsuburaya A, Imada T, Amano T, Matsumoto A, Nozawa A: Long-term total parenteral nutrition and osteoporosis: report of a case. Surg Today. 1993;23(11):1027-31. The serum level of parathormone and calcitonin were also within the normal ranges. Both the serum level of and urinary loss correlated closely to the amount of infused, but they were not influenced by the amount of (ergocalciferol) received. |
1(0,0,0,1) | Details |